We have used fluorescent fusion proteins stably expressed in HEK cells to detect directly the interaction between the sarcoplasmic reticulum Ca-ATPase (SERCA) and phospholamban (PLB) in living cells, in order to design PLB mutants for gene therapy. Ca 2+ cycling in muscle cells depends strongly on SERCA. Heart failure (HF), which contributes to 12% of US deaths, typically exhibits decreased SERCA activity, and several potential therapies for HF aim to increase SERCA activity. We are investigating the use of LOF-PLB mutants (PLB M ) as gene therapy vectors to increase SERCA activity. Active SERCA1a and WT-PLB, tagged at their N termini with fluorescent proteins (CFP and YFP), were coexpressed in stable HEK cell lines, and fluorescence resonance energy transfer (FRET) was used to detect their interaction directly. Phosphorylation of PLB, induced by forskolin, caused an increase in FRET from CFP-SERCA to YFP-PLB, indicating that SERCA inhibition can be relieved without dissociation of the complex. This suggests that a LOF mutant might bind to SERCA with sufficient affinity to complete effectively with WT-PLB, thus relieving SERCA inhibition. Therefore, we transiently expressed a series of PLB M in the CFP-SERCA/YFP-PLB cell line, and found decreased FRET, implying competition between PLB M and WT-PLB for binding to SERCA. These results establish this FRET assay as a rapid and quantitative means of screening PLB M for optimization of gene therapy to activate SERCA, as needed for gene therapy in HF.
Introduction
The sarcoplasmic reticulum (SR) Ca-ATPase (SERCA) is an integral membrane protein that pumps Ca 2+ from the cytosol into the SR lumen in muscle cells, thus maintaining low cytosolic [Ca 2+ ] in resting myocytes and potentiating contraction. In cardiac muscle, SERCA is inhibited at submicromolar [Ca 2+ ] by the single-pass transmembrane protein phospholamban (PLB), which can be phosphorylated to relieve SERCA inhibition [1] . Because SERCA activity or expression is reduced in many instances of heart failure (HF) [2, 3] , SERCA activation is a widely pursued goal for development of new therapies [3] . A gene therapy approach using rAAV to overexpress SERCA2a in heart tissue recently concluded phase II clinical trials with promising results [4] , and small-molecule SERCA activators are also being sought [5] . PLB-based approaches involve overexpression of a pseudophosphorylated PLB (S16E) [6] or a protein phosphatase I inhibitor to increase the phosphorylation of PLB [7] .
Here we explore expression of loss-of-function PLB mutants (PLB M ) to displace WT-PLB and activate SERCA.
Clear understanding of the mechanism by which PLB inhibits SERCA (Fig. 1A) is critical to designing an effective therapy. In the conventional model, supported by crosslinking and immunoprecipitation [8, 9] , SERCA inhibition can only be relieved by dissociation of PLB (''Dissociation Model'', Fig. 1A left) , but recent spectroscopic studies suggest that PLB remains bound to SERCA even after activation by PLB phosphorylation or Ca 2+ (''Subunit Model'', Fig. 1A right) [10] [11] [12] [13] . If this model is valid, an alternative therapeutic approach is suggested -a loss-of-function PLB mutant (PLB M ), introduced by gene therapy, could relieve SERCA inhibition if it binds tightly to SERCA, thus competing with endogenous PLB (Fig. 1B) . Evidence favoring this hypothesis in a reconstituted membrane system was recently published [14] . In the present study we have used fluorescent fusion proteins to detect directly the SERCA-PLB interaction in living cells. We used fluorescence microscopy to determine whether phosphorylation of YFP-PLB dissociates it from CFP-SERCA (Fig. 1A) , and to measure the ability of several PLB M to compete with YFP-PLB for CFP-SERCA binding (Fig. 1B) .
Materials and methods

Generation of stable cell lines expressing fluorescent fusion proteins
ECFP and EYFP mammalian vectors (Clonetech), containing the monomeric A206K mutation, were fused to the N-terminus of rabbit SERCA1a and canine PLB respectively. HEK293 cells (ATCC) were cultured in Dulbecco's Modified Eagle Medium (DMEM) without phenol red (Gibco/Invitrogen), supplemented with 10% fetal bovine serum (Atlanta Biologicals), at 37°C and 10% CO 2 . Cells were transiently transfected using Lipofectamine (Invitrogen), and stable cell lines were generated by G418 (Sigma) selection. Surviving clones expressing CFP-SERCA and YFP-PLB were further selected by fluorescence expression seen via fluorescence microscopy. The goal was to obtain measurable CFP fluorescence with a substantial excess of YFP over CFP.
Transient expression of non-fluorescent PLB M for competition measurements
Mutations in WT-PLB cDNA (resulting in PLB M in plasmid pRH132) were made using the QuickChange XLII mutagenesis kit (Agilent). PLB M were expressed in stable CFP-SERCA/YFP-PLB cell lines using 293fectin (Invitrogen). The amount of PLB M DNA used, volume of 293fectin, and time after transfection to maximize competition were all optimized so that PLB M expression was within 20% of that observed for the stable expression of YFP-PLB. Final conditions in a six-well plate required 1.25 pmol DNA with 9 lL 293fectin, and photobleaching measurements were acquired 48 h after transfection.
Western blots to quantify PLB and SERCA content
Cells were pelleted and homogenized 48 h after transient transfection with PLB M DNA or after 5 min. incubation in 40 lM forskolin [15] . Cell homogenates were run on 4-20% Tris-HCl gels (Criterion, Biorad) at 5 lg total homogenate protein along with standard curves of PLB (synthetic, WT or phosphorylated) and rabbit light SR ( [16] ), transferred to Immobilon-FL membranes (Millipore), and blocked for 1 h in 1x TBS/casein (Bio-rad). Primary antibodies for unphosphorylated PLB (Ab2D12, Abcam), PLB phosphorylated at S16 (Ab285, Merck), SERCA1 (IIH11, Abcam), or GFP variants (1GFP63, Abcam) were visualized using IR secondary antibodies (goat-anti-mouse or goat-anti-rabbit) from LI-COR Biosciences. Blots were scanned on the Odyssey (LI-COR Biosciences). Concentrations of PLB (phosphorylated and unphosphorylated forms) and PLB M were determined with high accuracy using synthetic standards run on the same blots as the cell homogenates [17, 18] . The slopes of standard curves were calculated from summed monomer and pentamer band intensities of three load concentrations for each standard (0.2, 0.4, and 0.8 pmol), using LI-COR Odyssey software and median, one-pixel background subtraction. Band intensities for both monomer and pentamer of YFP-PLB in cell homogenates were summed, and concentrations of both YFP-uPLB (C U ) and YFP-pPLB (C P ) were calculated by solving simultaneous equations, using the standard slopes [17, 18] . X P (the fraction of phosphorylated YFP-PLB) was then calculated by X P = C P /(C U + C P ) [17, 18] . A GFP antibody was used to label duplicate blots of the cell homogenates and indicated that total [YFP-PLB] was unaffected by incubation with forskolin. Blots with the SERCA antibody showed that all samples used in phosphorylation experiments had essentially the same CFP-SERCA expression levels (36 ± 5 nmol SERCA/g total protein). The molar ratio of YFP-PLB to SERCA was found to be 7.8 ± 0.9, and the transient expression of PLB M was consistently observed to be similar (7.1 ± 1.2).
Fluorescence resonance energy transfer (FRET) measurements in live HEK cells
Acceptor-selective photobleaching of cells co-expressing CFP-SERCA and YFP-PLB was done essentially as described previously [19] on an Eclipse TE200 microscope (Nikon Instruments), using CFP (excitation 430 nm/24, emission 470 nm/24) and YFP (excitation 500 nm/20, emission 535 nm/30) filters in automated filter wheels (Ludl) driven by MetaMorph software (Molecular Devices). Images were acquired using a 40x dry objective (0.55 numerical aperture), an X-Cite metal-halide lamp (EXFO), and a Cascade II CCD camera (Photometrics). A 10-ms exposure time was used in both channels with no neutral density filters, or a 100-ms exposure time was used with two neutral density filters, to reduce CFP photobleaching over the course of the experiment. Images at both emission wavelengths were then acquired at 20-s intervals before and after the start of 20-s exposures to high intensity light at YFP-specific excitation wavelengths. Photobleaching intervals were continued until YFP intensity was reduced to less than 5% of its starting value. The fractional decrease of fluorescence emission intensity of the donor (CFP-SERCA) caused by the presence of an acceptor (YFP-WT-PLB) is defined as the FRET efficiency 
, where F DA and F D are the fluorescence intensities in the presence and absence of acceptor, respectively. F DA was measured as the CFP intensity prior to the start of the YFP photobleach. F D was determined by the y-axis intercept of the linear fit to a data plot of YFP intensity (on x-axis) to CFP intensity (y-axis) over the course of the photobleach for each cell, to account for any CFP photobleaching and incomplete YFP photobleaching [19] . FRET values were calculated for all cells in each experimental condition and averaged together to determine FRET ave . To eliminate any changes in FRET ave due to differences in YFP-PLB expression levels, only cells with YFP intensities common to all experimental conditions were included in the FRET ave calculation.
Results
PLB phosphorylation
We expressed CFP-SERCA and YFP-PLB stably in HEK cells (at a molar ratio of 7.8 PLB/SERCA, to ensure saturation), then measured FRET using acceptor-selective photobleaching (Fig. 2) . The control FRET value of the parent cell line was 15.4 ± 1.2%, measured repeatedly and on different days over several weeks. This stable cell line was critical to evaluating perturbations due to PLB phosphorylation or competition with PLB M . FRET was calculated for every cell and averaged together based on initial YFP intensity.
FRET between CFP-SERCA and YFP-PLB increased significantly when PLB phosphorylation was induced by incubating the cells in forskolin (fsk), which activates the PKA pathway at adenylyl cyclase (Fig. 3A) . Immunoblots from the same cells, using antibodies specific for phosphorylated and unphosphorylated PLB, verify that phosphorylation of YFP-PLB increased substantially (from 51% to 87%) after forskolin treatment (Fig. 3B) . Increased FRET indicates increased SERCA-PLB association or a shorter donor-acceptor distance within the SERCA-PLB complex. If the Dissociation Model of SERCA regulation were valid, we would expect a decrease in FRET (Fig. 1A, left) . Thus this data clearly supports the Subunit Model (Fig. 1A, right) , in which phosphorylation changes the structure of the SERCA-PLB complex but does not dissociate it.
FRET measurements were used to calculate the distance between CFP and YFP before and after induction of PLB phosphorylation. Since FRET is a linear combination of the values for unphosphorylated (U) and phosphorylated (P) PLB, FRET = X U Â FRET U + X P Â FRET P , where X P (= 1 À X U ) is the fraction of PLB that is phosphorylated. Solving two simultaneous equations (before and after fsk), we find that the FRET values for the bound SERCA-PLB complex in the absence and presence of phosphorylation are FRE-T U = 0.07 ± 0.02 and FRET P = 0.23 ± 0.04. Since YFP-PLB is in large excess over CFP-SERCA, and since phosphorylation actually increases FRET, we assume that all CFP donors are participating in FRET. Assuming a single interprobe distance R in each case, R = (1/ FRET À 1) À1/6 Â 4.92 nm, giving R = 7.7 ± 0.4 nm (unphosphorylated) and 6.0 ± 0.2 nm (phosphorylated) [20] . Thus phosphorylation of PLB causes a change in the structure of the SERCA-PLB complex that decreases the CFP-YFP distance by DR = 1.7 ± 0.6 nm (p < 0.01, n = 8), consistent with the Subunit Model in Fig. 1A (right) .
PLB M competition
In contrast to the increased FRET induced by PLB phosphorylation, FRET between CFP-SERCA and YFP-PLB decreased significantly when unlabeled PLB M was added (Fig. 2, Fig. 4) . FRET measurements, following transient transfection of unlabeled PLB M into the stable CFP-SERCA/YFP-PLB HEK cell line, showed that all PLB M studied here compete effectively with YFP-PLB for SERCA binding, and several reduced FRET by approximately half (Fig. 4) . Expression levels of YFP-PLB and PLB M were similar, so a 50% decrease in FRET indicates that PLB M has a SERCA affinity similar to that of YFP-PLB. Further addition of YFP-PLB or a cytosolic protein (activation-induced deaminase, AID, used as a control) did not affect FRET (Fig. 4) , indicating that CFP-SERCA is saturated with YFP-PLB at the start of each competition experiment. The data in Fig. 4 were obtained from PLB variants based on the human sequence. Essentially the same results were obtained when these same mutations (WT, P21G, and S16E) were studied on the background of the monomeric AFA-PLB mutant (not shown).
Several PLB M compete effectively with YFP-PLB, with a potency (affinity) equal to or greater than that of unlabeled WT-PLB (Fig. 4) . The pseudo-phosphorylated mutant S16E, which rescues HF phenotypes in animal models when introduced via rAAV [6] , is a potent competitor, reducing CFP-YFP FRET by 45%. Two other LOF PLB M , P21G and L31A, also showed competition; this is important, since these mutants, unlike S16E, can still be phosphorylated by PKA at S16 and are thus preferable as gene therapy candidates. I40A, a superinhibitory (GOF) mutant of PLB [21] , showed similar competitive potency as WT and several LOF mutants (Fig. 4) .
In the competition experiments, we assume that the effect of unlabeled PLB M is to decrease the fraction of CFP-SERCA that is bound to YFP-PLB:
where FRET and FRET 0 are values observed before and after transient expression of unlabeled PLB M , and X B is the mole fraction of CFP-SERCA that remains bound to YFP-PLB after PLB M expression. Since the levels of YFP-PLB and PLB M are very similar, this means that, to a good approximation,
where K A is the affinity (1/K D ) of the PLB variant for CFP-SERCA. Since most of the PLB M tested, as well as WT-PLB, decreased FRET by about half (FRET/FRET 0 = 2) (Fig. 4) , each has about the same SERCA affinity as YFP-PLB. The exception is L31A, which gave FRET/FRET 0 = 0.7, so its SERCA affinity is about half that of the others.
Discussion
We showed previously that the SERCA-PLB interaction can be measured by FRET in living cells transiently expressing fluorescent fusion proteins CFP-SERCA and YFP-PLB [22] . The present study establishes a stable cell line to make precise FRET measurements over time (Fig. 2) , making it possible to compare the effects of numerous perturbations, such as PLB phosphorylation (Fig. 3) or the introduction of unlabeled PLB M to compete for SERCA binding (Fig. 2, Fig. 4 ). We used this assay to resolve several controversies regarding SERCA/PLB regulation. We found that FRET between SER-CA and PLB actually increases upon phosphorylation (Fig. 3) , clearly contradicting the Dissociation Model in favor of the Subunit Model (Fig. 1A) . Since PLB inhibition can be relieved by phosphorylation without decreasing SERCA affinity, a loss-of-function mutation might do the same (Fig. 1B) . This hypothesis was confirmed by the competition experiments, in which all mutants tested showed competition with WT-PLB for SERCA binding (Fig. 2, Fig. 4) .
This system offers the potential for probing the fundamental regulatory mechanism of the SERCA-PLB system in living cells [22, 23] , but our main motivation is therapeutic development. This direct and rapid competition assay in HEK cells provides a platform for evaluating further PLB M for gene therapy treatment of HF to activate SERCA (Fig. 1) . The effectiveness of S16E, the pseudophosphorylated PLB M , to compete significantly for SERCA binding in HEK cells (Fig. 4) helps explain its success as a gene therapy tool in animal models of HF [6] . Introduction of S16E-PLB into the human heart could cause chronic inotropic stimulation and is otherwise unregulated, so it is not optimal for gene therapy [24] . Better PLB M must be developed, with intact phosphorylation sites.
L31A-PLB is a well-known LOF mutant [14] , but it still competes with WT-PLB, albeit less effectively than S16E-PLB (Fig. 4) , in agreement with recent FRET experiments on purified proteins [14] . The P21G mutant, designed from magnetic resonance-based structural analysis [25] , provides encouraging evidence that a LOF PLB M with an intact phosphorylation site can be just as effective as S16E (Fig. 4) . Most of the PLB M tested show similar SERCA affinity as WT-PLB, but none shows significantly tighter binding (Fig. 4) . We are currently developing double mutants, combining LOF mutations with other mutations that increase SERCA affinity [25] . We envision an assortment of mutants to fine-tune SERCA activity to treat distinct HF syndromes. Our FRET competition assay in live cells provides a rapid and inexpensive method for screening potential therapeutic PLB M mutants before they are tested in animals or humans. This FRET assay also has the potential for high-throughput screening of small molecules as potential HF drugs to activate SERCA [14, 26] . shows increased YFP-PLB phosphorylation, by increased Ab285 (red, specific for pPLB) and decreased Ab2D12 (green, specific for uPLB). Quantitative densitometry, using purified uPLB and pPLB standards [17] , shows that phosphorylation increased from 51 ± 4% to 87 ± 5% in PLB monomer (shown) and pentamer bands. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) 
